IL7R Targeting Using OSE-127 Shows Robust Anti-Leukemic Activity in B-Cell Precursor Acute Lymphoblastic Leukemia Xenografts

Lennart Lenk, Irne Baccelli,Dorothee Winterberg, Frdrique Corallo,Fotini Vogiatzi,Lea Spory,Martin Schrappe,Gunnar Cario,Anna Laqua,Monika Brggemann,Nicolas Poirier,Denis Martin Schewe

Blood（2021）

引用 0|浏览19

暂无评分

摘要

Despite the favorable prognosis of B cell precursor acute lymphoblastic leukemia (BCP-ALL), relapse remains a clinical challenge. Antibody-based immunotherapies like Blinatumomab have improved BCP-ALL outcome, yet these can quickly turn ineffective due to CD19 antigen escape. Therefore, novel targeted immunotherapy options are urgently needed.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要